ARTS II
ARTS II
Arterial Revascularization Therapy Study part II. A trial comparing the sirolimus-eluting Bx Velocity® Balloon expandable stent in patients with multivessel disease, ischaemia, and no prior coronary interventions.Primary endpoint 1-year major acute coronary and cerebrovascular events (MACCE) compared with the 1-year MACCE of ARTS I.
Conclusion MACCE is 3% in ARTS II compared to 4% with CABG and 8% with percutaneous coronary intervention in ARTS I.